Natural killer T cell anergy, co-stimulatory molecules and immunotherapeutic interventions

Human Immunology

Volumn 75, Issue 3, 2014, Pages 250-260

  Singh, Avadhesh Kumar ^a   Gaur, Poonam ^a   Das, Satya N ^a  

^a ALL INDIA INSTITUTE OF MEDICAL SCIENCES   (India)

Author keywords

[No Author keywords available]

Indexed keywords

ANIMALS; CLINICAL TRIALS AS TOPIC; CLONAL ANERGY; HUMANS; IMMUNOTHERAPY, ADOPTIVE; LYMPHOCYTE ACTIVATION; MOLECULAR TARGETED THERAPY; NATURAL KILLER T-CELLS; NEOPLASMS; RECEPTOR CROSS-TALK;

EID: 84893780612     PISSN: 01988859     EISSN: 18791166     Source Type: Journal    
DOI: 10.1016/j.humimm.2013.12.004     Document Type: Review

References (95)

1. Bendelac A., Savage P.B., Teyton L. The biology of NKT cells. Annu Rev Immunol 2007, 25:297-336.
2. Godfrey D.I., Stankovic S., Baxter A.G. Raising the NKT cell family. Nat Immunol 2010, 11:197-206.
3. Matsuda J.L., Naidenko O.V., Gapin L., Nakayama T., Taniguchi M., Wang C.R., et al. Tracking the response of natural killer T cells to a glycolipid antigen using CD1d tetramers. J Exp Med 2000, 192:741-754.
4. Borg N.A., Wun K.S., Kjer-Nielsen L., Wilce M.C.J., Pellicci D.G., Koh R., et al. CD1d-lipid-antigen recognition by the semi-invariant NKT T-cell receptor. Nature 2007, 448:44-49.
5. Berzins S.P., Smyth M.J., Baxter A.G. Presumed guilty: natural killer T cell defects and human disease. Nat Rev Immunol 2011, 11:131-142.
6. Michel M.-L., Keller A.C., Paget C., Fujio M., Trottein F., Savage P.B., et al. Identification of an IL-17-producing NK1.1neg iNKT cell population involved in airway neutrophilia. J Exp Med 2007, 204:995-1001.
7. Monteiro M., Almeida C.F., Agua-Doce A., Graca L. Induced IL-17-producing invariant NKT cells require activation in presence of TGF-β and IL-1β. J Immunol 2013, 190:805-811.
8. Van den Heuvel M.J., Garg N., Van Kaer L., Haeryfar S.M.M. NKT cell costimulation: experimental progress and therapeutic promise. Trends Mol Med 2011, 17:65-77.
9. Terabe M., Berzofsky J.A. The role of NKT cells in tumor immunity. Adv Cancer Res 2008, 101:277-348.
10. Simoni Y., Diana J., Ghazarian L., Beaudoin L., Lehuen A. Therapeutic manipulation of natural killer (NK) T cells in autoimmunity: are we close to reality?. Clin Exp Immunol 2013, 171:8-19.
11. Cerundolo V., Silk J.D., Masri S.H., Salio M. Harnessing invariant NKT cells in vaccination strategies. Nat Rev Immunol 2009, 9:28-38.
12. Giaccone G., Punt C.J.A., Ando Y., Ruijter R., Nishi N., Peters M., et al. A phase I study of the natural killer T-cell ligand alpha-galactosylceramide (KRN7000) in patients with solid tumors. Clin Cancer Res 2002, 8:3702-3709.
13. Nieda M., Okai M., Tazbirkova A., Lin H., Yamaura A., Ide K., et al. Therapeutic activation of Valpha24+Vbeta11+ NKT cells in human subjects results in highly coordinated secondary activation of acquired and innate immunity. Blood 2004, 103:383-389.
14. Ishikawa A., Motohashi S., Ishikawa E., Fuchida H., Higashino K., Otsuji M., et al. A phase I study of alpha-galactosylceramide (KRN7000)-pulsed dendritic cells in patients with advanced and recurrent non-small cell lung cancer. Clin Cancer Res 2005, 11:1910-1917.
15. Chang D.H., Osman K., Connolly J., Kukreja A., Krasovsky J., Pack M., et al. Sustained expansion of NKT cells and antigen-specific T cells after injection of alpha-galactosyl-ceramide loaded mature dendritic cells in cancer patients. J Exp Med 2005, 201:1503-1517.
16. Motohashi S., Ishikawa A., Ishikawa E., Otsuji M., Iizasa T., Hanaoka H., et al. A phase I study of in vitro expanded natural killer T cells in patients with advanced and recurrent non-small cell lung cancer. Clin Cancer Res 2006, 12:6079-6086.
17. Uchida T., Horiguchi S., Tanaka Y., Yamamoto H., Kunii N., Motohashi S., et al. Phase I study of alpha-galactosylceramide-pulsed antigen presenting cells administration to the nasal submucosa in unresectable or recurrent head and neck cancer. Cancer Immunol Immunother 2008, 57:337-345.
18. Motohashi S., Nagato K., Kunii N., Yamamoto H., Yamasaki K., Okita K., et al. A Phase I-II Study of α-galactosylceramide-pulsed IL-2/GM-CSF-cultured peripheral blood mononuclear cells in patients with advanced and recurrent non-small cell lung cancer. J Immunol 2009, 182:2492-2501.
19. Kunii N., Horiguchi S., Motohashi S., Yamamoto H., Ueno N., Yamamoto S., et al. Combination therapy of in vitro-expanded natural killer T cells and alpha-galactosylceramide-pulsed antigen-presenting cells in patients with recurrent head and neck carcinoma. Cancer Sci 2009, 100:1092-1098.
20. Yamasaki K., Horiguchi S., Kurosaki M., Kunii N., Nagato K., Hanaoka H., et al. Induction of NKT cell-specific immune responses in cancer tissues after NKT cell-targeted adoptive immunotherapy. Clin Immunol 2011, 138:255-265.
21. Parekh V.V., Wilson M.T., Olivares-Villagómez D., Singh A.K., Wu L., Wang C., et al. Glycolipid antigen induces long-term natural killer T cell anergy in mice. J Clin Invest 2005, 115:2572-2583.
22. Godfrey D.I., MacDonald H.R., Kronenberg M., Smyth M.J., Van Kaer L. NKT cells: what's in a name?. Nat Rev Immunol 2004, 4:231-237.
23. Eberl G., Lees R., Smiley S.T., Taniguchi M., Grusby M.J., MacDonald H.R. Tissue-specific segregation of CD1d-dependent and CD1d-independent NK T cells. J Immunol 1999, 162:6410-6419.
24. Singh A.K., Shukla N.K., Das S.N. Altered invariant natural killer T cell subsets and functions in patients with oral squamous cell carcinoma. Scand J Immunol 2013, 78:468-477.
25. Harner S., Noessner E., Nadas K., Leumann-Runge A., Schiemann M., Faber F.L., et al. Cord blood Vα24-Vβ11 natural killer T cells display a Th2-chemokine receptor profile and cytokine responses. PLoS One 2011, 6:e15714.
26. Exley M.A., Hou R., Shaulov A., Tonti E., Dellabona P., Casorati G., et al. Selective activation, expansion, and monitoring of human iNKT cells with a monoclonal antibody specific for the TCR alpha-chain CDR3 loop. Eur J Immunol 2008, 38:1756-1766.
27. Gadola S.D., Dulphy N., Salio M., Cerundolo V. Valpha24-JalphaQ-independent, CD1d-restricted recognition of alpha-galactosylceramide by human CD4(+) and CD8alphabeta(+) T lymphocytes. J Immunol 2002, 168:5514-5520.
28. O'Reilly V., Zeng S.G., Bricard G., Atzberger A., Hogan A.E., Jackson J., et al. Distinct and overlapping effector functions of expanded human CD4, CD8α and CD4CD8α invariant natural killer T cells. PLoS One 2011, 6:e28648.
29. Takahashi T., Chiba S., Nieda M., Azuma T., Ishihara S., Shibata Y., et al. Cutting edge: analysis of human V alpha 24+CD8+ NK T cells activated by alpha -galactosylceramide-pulsed monocyte-derived dendritic cells. J Immunol 2002, 168:3140-3144.
30. Hammond K.J., Pelikan S.B., Crowe N.Y., Randle-Barrett E., Nakayama T., Taniguchi M., et al. NKT cells are phenotypically and functionally diverse. Eur J Immunol 1999, 29:3768-3781.
31. Niemeyer M., Darmoise A., Mollenkopf H.-J., Hahnke K., Hurwitz R., Besra G.S., et al. Natural killer T-cell characterization through gene expression profiling: an account of versatility bridging T helper type 1 (Th1), Th2 and Th17 immune responses. Immunology 2008, 123:45-56.
32. Rachitskaya A.V., Hansen A.M., Horai R., Li Z., Villasmil R., Luger D., et al. Cutting edge: NKT cells constitutively express IL-23 receptor and RORgammat and rapidly produce IL-17 upon receptor ligation in an IL-6-independent fashion. J Immunol 2008, 180:5167-5171.
33. Engel I., Zhao M., Kappes D., Taniuchi I., Kronenberg M. The transcription factor Th-POK negatively regulates Th17 differentiation in Vα14i NKT cells. Blood 2012, 120:4524-4532.
34. Michel M.-L., Mendes-da-Cruz D., Keller A.C., Lochner M., Schneider E., Dy M., et al. Critical role of ROR-γt in a new thymic pathway leading to IL-17-producing invariant NKT cell differentiation. Proc Natl Acad Sci USA 2008, 105:19845-19850.
35. Terashima A., Watarai H., Inoue S., Sekine E., Nakagawa R., Hase K., et al. A novel subset of mouse NKT cells bearing the IL-17 receptor B responds to IL-25 and contributes to airway hyperreactivity. J Exp Med 2008, 205:2727-2733.
36. Watarai H., Sekine-Kondo E., Shigeura T., Motomura Y., Yasuda T., Satoh R., et al. Development and function of invariant natural killer T cells producing TH2- and TH17-cytokines. PLoS Biol 2012, 10:e1001255.
37. Moreira-Teixeira L., Resende M., Devergne O., Herbeuval J.-P., Hermine O., Schneider E., et al. Rapamycin combined with TGF-β converts human invariant NKT cells into suppressive Foxp3+ regulatory cells. J Immunol 2012, 188:624-631.
38. Chung Y., Nurieva R., Esashi E., Wang Y.-H., Zhou D., Gapin L., et al. A critical role of costimulation during intrathymic development of invariant NK T cells. J Immunol 2008, 180:2276-2283.
39. Akbari O., Stock P., Meyer E.H., Freeman G.J., Sharpe A.H., Umetsu D.T., et al. ICOS/ICOSL interaction is required for CD4+ invariant NKT cell function and homeostatic survival. J Immunol 2008, 180:5448-5456.
40. Kadri N., Korpos E., Gupta S., Briet C., Löfbom L., Yagita H., et al. CD4+ type II NKT cells mediate ICOS and programmed death-1-dependent regulation of type 1 diabetes. J Immunol 2012, 188:3138-3149.
41. Watanabe S., Ohnuki K., Hara Y., Ishida Y., Ikarashi Y., Ogawa S., et al. Suppression of Con A-induced hepatitis induction in ICOS-deficient mice. Immunol Lett 2010, 128:51-58.
42. Zietara N., Łyszkiewicz M., Krueger A., Weiss S. ICOS-dependent stimulation of NKT cells by marginal zone B cells. Eur J Immunol 2011, 41:3125-3134.
43. Williams J.A., Lumsden J.M., Yu X., Feigenbaum L., Zhang J., Steinberg S.M., et al. Regulation of thymic NKT cell development by the B7-CD28 costimulatory pathway. J Immunol 2008, 181:907-917.
44. Zheng X., Zhang H., Yin L., Wang C.-R., Liu Y., Zheng P. Modulation of NKT cell development by B7-CD28 interaction: an expanding horizon for costimulation. PLoS One 2008, 3:e2703.
45. Wang X.F., Lei Y., Chen M., Chen C.B., Ren H., Shi T.D. PD-1/PDL1 and CD28/CD80 pathways modulate natural killer T cell function to inhibit hepatitis B virus replication. J Viral Hepat 2013, 20(Suppl. 1):27-39.
46. Smyth M.J., Crowe N.Y., Hayakawa Y., Takeda K., Yagita H., Godfrey D.I. NKT cells - conductors of tumor immunity?. Curr Opin Immunol 2002, 14:165-171.
47. Diana J., Griseri T., Lagaye S., Beaudoin L., Autrusseau E., Gautron A.-S., et al. NKT cell-plasmacytoid dendritic cell cooperation via OX40 controls viral infection in a tissue-specific manner. Immunity 2009, 30:289-299.
48. Shimizu K., Asakura M., Shinga J., Sato Y., Kitahara S., Hoshino K., et al. Invariant NKT cells induce plasmacytoid dendritic cell (DC) cross-talk with conventional DCs for efficient memory CD8+ T cell induction. J Immunol 2013, 190:5609-5619.
49. Zaini J., Andarini S., Tahara M., Saijo Y., Ishii N., Kawakami K., et al. OX40 ligand expressed by DCs costimulates NKT and CD4 Th cell antitumor immunity in mice. J Clin Invest 2007, 117:3330-3338.
50. Vinay D.S., Choi B.K., Bae J.S., Kim W.Y., Gebhardt B.M., Kwon B.S. CD137-deficient mice have reduced NK/NKT cell numbers and function, are resistant to lipopolysaccharide-induced shock syndromes, and have lower IL-4 responses. J Immunol 2004, 173:4218-4229.
51. Lee S.-W., Salek-Ardakani S., Mittler R.S., Croft M. Hypercostimulation through 4-1BB distorts homeostasis of immune cells. J Immunol 2009, 182:6753-6762.
52. Uldrich A.P., Crowe N.Y., Kyparissoudis K., Pellicci D.G., Zhan Y., Lew A.M., et al. NKT cell stimulation with glycolipid antigen in vivo: costimulation-dependent expansion, Bim-dependent contraction, and hyporesponsiveness to further antigenic challenge. J Immunol 2005, 175:3092-3101.
53. Parekh V.V., Lalani S., Kim S., Halder R., Azuma M., Yagita H., et al. PD-1/PD-L blockade prevents anergy induction and enhances the anti-tumor activities of glycolipid-activated invariant NKT cells. J Immunol 2009, 182:2816-2826.
54. Kawano T., Cui J., Koezuka Y., Toura I., Kaneko Y., Motoki K., et al. CD1d-restricted and TCR-mediated activation of valpha14 NKT cells by glycosylceramides. Science 1997, 278:1626-1629.
55. Chang W.-S., Kim J.-Y., Kim Y.-J., Kim Y.-S., Lee J.-M., Azuma M., et al. Cutting edge: programmed death-1/programmed death ligand 1 interaction regulates the induction and maintenance of invariant NKT cell anergy. J Immunol 2008, 181:6707-6710.
56. Iyoda T., Ushida M., Kimura Y., Minamino K., Hayuka A., Yokohata S., et al. Invariant NKT cell anergy is induced by a strong TCR-mediated signal plus co-stimulation. Int Immunol 2010, 22:905-913.
57. Durgan K., Ali M., Warner P., Latchman Y.E. Targeting NKT cells and PD-L1 pathway results in augmented anti-tumor responses in a melanoma model. Cancer Immunol Immunother 2011, 60:547-558.
58. Kee S.-J., Kwon Y.-S., Park Y.-W., Cho Y.-N., Lee S.-J., Kim T.-J., et al. Dysfunction of natural killer T cells in patients with active Mycobacterium tuberculosis infection. Infect Immun 2012, 80:2100-2108.
59. Keir M.E., Butte M.J., Freeman G.J., Sharpe A.H. PD-1 and its ligands in tolerance and immunity. Annu Rev Immunol 2008, 26:677-704.
60. Butte M.J., Keir M.E., Phamduy T.B., Sharpe A.H., Freeman G.J. Programmed death-1 ligand 1 interacts specifically with the B7-1 costimulatory molecule to inhibit T cell responses. Immunity 2007, 27:111-122.
61. Akbari O., Stock P., Singh A.K., Lombardi V., Lee W.-L., Freeman G.J., et al. PD-L1 and PD-L2 modulate airway inflammation and iNKT-cell-dependent airway hyperreactivity in opposing directions. Mucosal Immunol 2010, 3:81-91.
62. Chen S., Ndhlovu L.C., Takahashi T., Takeda K., Ikarashi Y., Kikuchi T., et al. Co-inhibitory roles for glucocorticoid-induced TNF receptor in CD1d-dependent natural killer T cells. Eur J Immunol 2008, 38:2229-2240.
63. Iwata A., Watanabe N., Oya Y., Owada T., Ikeda K., Suto A., et al. Protective roles of B and T lymphocyte attenuator in NKT cell-mediated experimental hepatitis. J Immunol 2010, 184:127-133.
64. Kinjo Y., Tupin E., Wu D., Fujio M., Garcia-Navarro R., Benhnia M.R.-E.-I., et al. Natural killer T cells recognize diacylglycerol antigens from pathogenic bacteria. Nat Immunol 2006, 7:978-986.
65. Florence W.C., Xia C., Gordy L.E., Chen W., Zhang Y., Scott-Browne J., et al. Adaptability of the semi-invariant natural killer T-cell receptor towards structurally diverse CD1d-restricted ligands. EMBO J 2009, 28:3579-3590.
66. McCarthy C., Shepherd D., Fleire S., Stronge V.S., Koch M., Illarionov P.A., et al. The length of lipids bound to human CD1d molecules modulates the affinity of NKT cell TCR and the threshold of NKT cell activation. J Exp Med 2007, 204:1131-1144.
67. Zhou D., Mattner J., Cantu C., Schrantz N., Yin N., Gao Y., et al. Lysosomal glycosphingolipid recognition by NKT cells. Science 2004, 306:1786-1789.
68. Porubsky S., Speak A.O., Luckow B., Cerundolo V., Platt F.M., Gröne H.-J. Normal development and function of invariant natural killer T cells in mice with isoglobotrihexosylceramide (iGb3) deficiency. Proc Natl Acad Sci USA 2007, 104:5977-5982.
69. Speak A.O., Salio M., Neville D.C.A., Fontaine J., Priestman D.A., Platt N., et al. Implications for invariant natural killer T cell ligands due to the restricted presence of isoglobotrihexosylceramide in mammals. Proc Natl Acad Sci USA 2007, 104:5971-5976.
70. Christiansen D., Milland J., Mouhtouris E., Vaughan H., Pellicci D.G., McConville M.J., et al. Humans lack iGb3 due to the absence of functional iGb3-synthase: implications for NKT cell development and transplantation. PLoS Biol 2008, 6:e172.
71. Li Y., Teneberg S., Thapa P., Bendelac A., Levery S.B., Zhou D. Sensitive detection of isoglobo and globo series tetraglycosylceramides in human thymus by ion trap mass spectrometry. Glycobiology 2008, 18:158-165.
72. Sanderson J.P., Brennan P.J., Mansour S., Matulis G., Patel O., Lissin N., et al. CD1d protein structure determines species-selective antigenicity of isoglobotrihexosylceramide (iGb3) to invariant NKT cells. Eur J Immunol 2013, 43:815-825.
73. Brennan P.J., Tatituri R.V.V., Brigl M., Kim E.Y., Tuli A., Sanderson J.P., et al. Invariant natural killer T cells recognize lipid self antigen induced by microbial danger signals. Nat Immunol 2011, 12:1202-1211.
74. Inafuku M., Li C., Kanda Y., Kawamura T., Takeda K., Oku H., et al. Beta-glucosylceramide administration (i.p.) activates natural killer T cells in vivo and prevents tumor metastasis in mice. Lipids 2012, 47:581-591.
75. O'Konek J.J., Kato S., Takao S., Izhak L., Xia Z., Illarionov P., et al. β-Mannosylceramide activates type I natural killer T cells to induce tumor immunity without inducing long-term functional anergy. Clin Cancer Res 2013, 19:4404-4411.
76. Fujii S.-I., Shimizu K., Hemmi H., Fukui M., Bonito A.J., Chen G., et al. Glycolipid alpha-C-galactosylceramide is a distinct inducer of dendritic cell function during innate and adaptive immune responses of mice. Proc Natl Acad Sci USA 2006, 103:11252-11257.
77. Zhou Z., Zhang C., Xia C., Chen W., Zhu H., Shang P., et al. Enhanced antitumor effects by chemical modified IGb3 analogues. Mol Cancer Ther 2011, 10:1375-1384.
78. Kim C.H., Johnston B., Butcher E.C. Trafficking machinery of NKT cells: shared and differential chemokine receptor expression among Valpha24+ Vbeta11+ NKT cell subsets with distinct cytokine-producing capacity. Blood 2002, 100:11-16.
79. Germanov E., Veinotte L., Cullen R., Chamberlain E., Butcher E.C., Johnston B. Critical role for the chemokine receptor CXCR6 in homeostasis and activation of CD1d-restricted NKT cells. J Immunol 2008, 181:81-91.
80. Cullen R., Germanov E., Shimaoka T., Johnston B. Enhanced tumor metastasis in response to blockade of the chemokine receptor CXCR6 is overcome by NKT cell activation. J Immunol 2009, 183:5807-5815.
81. Wen X., Rao P., Carreño L.J., Kim S., Lawrenczyk A., Porcelli S.A., et al. Human CD1d knock-in mouse model demonstrates potent antitumor potential of human CD1d-restricted invariant natural killer T cells. Proc Natl Acad Sci USA 2013, 110:2963-2968.
82. Tahir S.M., Cheng O., Shaulov A., Koezuka Y., Bubley G.J., Wilson S.B., et al. Loss of IFN-gamma production by invariant NK T cells in advanced cancer. J Immunol 2001, 167:4046-4051.
83. Kenna T., Golden-Mason L., Porcelli S.A., Koezuka Y., Hegarty J.E., O'Farrelly C., et al. NKT cells from normal and tumor-bearing human livers are phenotypically and functionally distinct from murine NKT cells. J Immunol 2003, 171:1775-1779.
84. Motohashi S., Kobayashi S., Ito T., Magara K.K., Mikuni O., Kamada N., et al. Preserved IFN-alpha production of circulating Valpha24 NKT cells in primary lung cancer patients. Int J Cancer 2002, 102:159-165.
85. Metelitsa L.S., Wu H.-W., Wang H., Yang Y., Warsi Z., Asgharzadeh S., et al. Natural killer T cells infiltrate neuroblastomas expressing the chemokine CCL2. J Exp Med 2004, 199:1213-1221.
86. Van der Vliet H.J., Molling J.W., von Blomberg B.M.E., Kölgen W., Stam A.G., de Gruijl T.D., et al. Circulating Valpha24+Vbeta11+ NKT cell numbers and dendritic cell CD1d expression in hepatitis C virus infected patients. Clin Immunol 2005, 114:183-189.
87. Wilson M.T., Johansson C., Olivares-Villagómez D., Singh A.K., Stanic A.K., Wang C.-R., et al. The response of natural killer T cells to glycolipid antigens is characterized by surface receptor down-modulation and expansion. Proc Natl Acad Sci USA 2003, 100:10913-10918.
88. Crowe N.Y., Uldrich A.P., Kyparissoudis K., Hammond K.J.L., Hayakawa Y., Sidobre S., et al. Glycolipid antigen drives rapid expansion and sustained cytokine production by NK T cells. J Immunol 2003, 171:4020-4027.
89. Harada M., Seino K.-I., Wakao H., Sakata S., Ishizuka Y., Ito T., et al. Down-regulation of the invariant Valpha14 antigen receptor in NKT cells upon activation. Int Immunol 2004, 16:241-247.
90. Eberl G., MacDonald H.R. Rapid death and regeneration of NKT cells in anti-CD3epsilon- or IL-12-treated mice: a major role for bone marrow in NKT cell homeostasis. Immunity 1998, 9:345-353.
91. Mueller D.L., Jenkins M.K., Schwartz R.H. Clonal expansion versus functional clonal inactivation: a costimulatory signalling pathway determines the outcome of T cell antigen receptor occupancy. Annu Rev Immunol 1989, 7:445-480.
92. Kojo S., Elly C., Harada Y., Langdon W.Y., Kronenberg M., Liu Y.-C. Mechanisms of NKT cell anergy induction involve Cbl-b-promoted monoubiquitination of CARMA1. Proc Natl Acad Sci USA 2009, 106:17847-17851.
93. Thien C.B., Langdon W.Y. Cbl: many adaptations to regulate protein tyrosine kinases. Nat Rev Mol Cell Biol 2001, 2:294-307.
94. Fang D., Liu Y.C. Proteolysis-independent regulation of PI3K by Cbl-b-mediated ubiquitination in T cells. Nat Immunol 2001, 2:870-875.
95. Schulze-Luehrmann J., Ghosh S. Antigen-receptor signaling to nuclear factor kappa B. Immunity 2006, 25:701-715.